8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes-Reference-Cited by-同舟云学术

8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

Published:2007-12-01 Issue:26 Volume:50 Page:6450-6453
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Eckhardt Matthias¹,Langkopf Elke¹,Mark Michael¹,Tadayyon Moh¹,Thomas Leo¹,Nar Herbert¹,Pfrengle Waldemar¹,Guth Brian¹,Lotz Ralf¹,Sieger Peter¹,Fuchs Holger¹,Himmelsbach Frank¹

Affiliation:

1. Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm701280z

Reference24 articles.

1. http://www.eatlas.idf.org.

2. Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV

3. The Therapeutic Potential of Inhibitors of Dipeptidyl Peptidase IV (DPP IV) and Related Proline-Specific Dipeptidyl Aminopeptidases